Потенційні впливи коронавірусів на серцево-судинну систему в умовах пандемії COVID-19

Л.О. Ткаченко, О.А. Єпанчінцева, Б.М. Тодуров

Література  

1. Alhogbani T. Acute myocarditis associated with novel Middle east respiratory syndrome coronavirus. Ann Saudi Med. 2016;36 (1):78–80. doi: 10.5144/0256-4947.2016.78
2. Alon D, Stein GY, Korenfeld R. Fuchs S. Predictors and outcomes of infection-related hospital admissions of heart failure patients. PLoS One. 2013;23;8 (8):e72476. doi: 10.1371/journal.pone.0072476 eCollection 2013.
3. Arentz M, Yim E, Klaff L. et al. Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State. JAMA. 2020;19. doi: 10.1001/jama.2020.4326 [Epub ahead of print].
4. ASE Statement on Protection of Patients and Echocardiography Service Providers During the 2019 Novel Coronavirus Outbreak. ASEcho.org
5. Badawi A, Ryoo SG. Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis. Int J Infect. Dis. 2016;49:129–133. doi: 10.1016/j.ijid.2016.06.015 Epub 2016 Jun 21.
6. Barnes M, Heywood AE, Mahimbo A. et al. Acute myocardial infarction and influenza: a meta-analysis of case-control studies. Heart. 2015;101 (21):1738–1747. doi: 10.1136/ heartjnl-2015-307691
7. Brigham and Women’s Hospital COVID-19 Critical Care Clinical Guidelines. http://www. covidprotocols.org/
8. Booth CM, Matukas LM, Tomlinson GA. et al. Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. JAMA. 2003;289:2801–2809.
9. Chan JWM, Ng CK, Chan YH. et al. Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS). Thorax. 2003;58:686–689.
10. Chen C, Zhou Y, Wang D.W. ARS-CoV-2: a potential novel etiology of fulminant myocarditis. Herz. 2020;5. doi: 10.1007/s00059-020-04909-z
11. Chen C, Chen C, Yan JT. et al. Analysis of myocardial injury in patients with COVID19 and association between concomitant cardiovascular diseases and severity of COVID-19. Zhonghua Xin Xue Guan Bing Za Zhi. 2020. 6;48 (0). E008. doi: 10.3760/ cma.j.cn112148-20200225-00123
12. Choi AD, Abbara S, Branch KR. et al. SCCT Guidance for use of cardiac computed tomography amidst the COVID-19 Pandemic. J Cardiovasc Comput Tomogr. 2016;10 (6):435–449. doi: 10.1016/j.jcct.2016.10.002
13. Elkind MS, Harrington RA, Benjamin IJ. Role of the American Heart Association in the Global COVID-19 Pandemic. Circulation. 2020. Mar 17. doi: 10.1161/CIRCULATIONAHA.120.046749 [Epub ahead of print].
14. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?. Lancet Respir Med. 2020. Mar 11. pii:S2213- 2600(20)30116-8. doi: 10.1016/S2213-2600(20)30116-8. [Epub ahead of print].
15. Ferrario CM, Jessup J, Gallagher PE. et al. Effects of renin-angiotensin system blockage on renal angiotensin-(1-7) forming enzymes and receptors. Kidney Int. 2005;68:2189–2196.
16. Frederik GPW, Shah PB, Aronow HD. et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: From ACC’s Interventional Council and SCAI. JACC. March 2020. doi: 10.1016/j.jacc.2020.03.021.
17. Gao Y. Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol. 2020. Mar 17. doi: 10.1002/jmv.25770
18. Grasselli G, Pesenti A, Cecconi M. Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy. JAMA. 2020. Published Online 13.03.2020. doi: 10.1001/jama.2020.4031 
19. Guan WJ, Ni ZY, Hu Y. et al. Clinical Characteristics of Coronavirus Disease 2019 in China. New Eng J Med. 2020; doi: 10.1056/NEJMoa2002032. [Epub ahead of print].
20. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID19 https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-ahastatement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
21. Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2020;16. pii: ehaa190. doi: 10.1093/ eurheartj/ehaa190 [Epub ahead of print].
22. Hui H, Zhang Y, Yang X. et al. Clinical and radiographic features of cardiac injury in patients with 2019 novel coronavirus pneumonia. Medrxiv.org, posted 27.02.2020. doi: 10.1101/20 20.02.24.20027052
23. Hypertension Canada’s Statement on: Hypertension, ACE-Inhibitors and Angiotensin Receptor Blockers and COVID-19. https://hypertension.ca/wp-content/uploads/2020/03/ 2020-30-15-Hypertension-Canada-Statement-on-COVID-19-ACEi-ARB.pdf.
24. Kwong JC, Schwartz KL, Campitelli MA. et al. Acute myocardial infarction after laboratoryconfirmed influenza infection. New Engl. J. Med. 2018;378 (4):345–353. doi: 10.1056/ NEJMoa1702090
25. Lauer SA, Grantz KH, Bi Q. et al. The Incubation Period of Coronavirus Disease 2019 (COVID-19) From Publicly Reported Confirmed Cases: Estimation and Application. Ann. Intern. Med. 2020. doi: 10.7326/M20-0504 [Epub ahead of print].
26. Li B, Yang J, Zhao F. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin. Res. Cardiol. 2020. doi: 10.1007/s00392-020-01626-9.
27. Liu K, Fang YY, Deng Y. et al. Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin. Med. J. (Engl). 2020. 7. doi: 10.1097/ CM9.0000000000000744
28. Mahmud E. The Evolving Pandemic of COVID-19 and Interventional Cardiology. Position of President of Society for Cardiovascular Angiography & Interventions. www.scai.org, 16.03.2020 
29. Marsousi N, Daali Y, Fontana P. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin. Pharmacokinet. 2018;57 (10):1347–1354. doi: 10.1007/s40262-018-0637-6
30. Mehra MR, Ruschitzka F. COVID-19 Illness and Heart Failure: A Missing Link?. JACC: Heart Failure. 2020: doi: 10.1016/j.jchf.2020.03.004 
31. Nguyen JL, Yang W, Ito K. et al. Seasonal Influenza Infections and Cardiovascular Disease Mortality. JAMA Cardiol. 2016;1 (3):274–281. doi: 10.1001/jamacardio.2016.0433
32. NHSBT/BTS guidance for clinicians on consent for solid organ transplantation in adults and living organ donation in the context of the COVID-19 pandemic. https://bts.org.uk/ wp-content/uploads/2020/03/NHSBT-BTS-consent-guidance-COVID-19-26.3.20.pdf.
33. Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID19) in China [Chinese]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020;41 (2):145–151. doi: 10.3760/cma.j.issn.0254-6450.2020.02.003 [Epub ahead of print]
34. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/ News/
35. Ruan Q, Yang K, Wang W. et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020. Mar 3. doi: 10.1007/s00134-020-05991-x
36. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) – United States, February 12 – March 16, 2020. MMWR Morb Mortal. Wkly Rep. 2020;69 (12):343–346. doi: 10.15585/mmwr.mm6912e2
37. Veronese G, Ammirati E, Cipriani M, Frigerio M. Fulminant myocarditis: Characteristics, treatment, and outcomes. Anatol. J. Cardiol. 2018;19 (4):279–286. doi: 10.14744/ AnatolJCardiol.2017.8170 Epub 2018 Mar 13.
38. Wang D, Hu B, Hu C. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/ jama.2020.1585 
39. Watkins J. Preventing a covid-19 pandemic. BMJ. 2020; m810. doi: 10.1136/bmj.m810 
40. WHO Coronavirus disease 2019 (COVID-19). Situation Report–41. https://www.who. int/docs/default-source/coronaviruse/situation-reports/20200301-sitrep-41-covid-19. pdf?sfvrsn=6768306d_2
41. World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID19). Geneva: WHO; 2020. Available from: https://www.who.int/docs/ default-source/coronaviruse/whochina-joint-mission-on-covid-19-final-report.pdf]
42. Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi: 10.1001/jama.2020.2648 
43. Xiong TY, Redwood S, Prendergast B, Chen M. Coronaviruses and the cardiovascular system: acute and long-term implications. Eur. Heart J. Published online 18 March 2020. doi: 10.1093/eurheartj/ehaa231 
44. Xu Z, Shi L, Wang Y. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020. Feb 18. pii:S2213-2600(20)30076-X.
45. Yang J, Zheng Y, Gou X. et al. Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Intern. J. Infectious Diseases. 2020. doi: 10.1016/j.ijid.2020.03.017 
46. Yang X, Yu Y, Xu J. et al. Clinical course and outcomes of critically ill patients with SARSCoV2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020. 24. pii:S2213-2600(20)30079-5. doi: 10.1016/S2213- 2600(20)30079-5 [Epub ahead of print]
47. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020. doi: 10.1007/s00134-020-05993-9 
48. Zheng Y, Ma Y, Zhang J. et al. COVID-19 and the cardiovascular system. Nat. Rev. Cardiol. 2020. Mar 5. doi: 10.1038/s41569-020-0360-5 [Epub ahead of print]

49. Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-1062. doi: 10.1016/S0140-6736(20)30566-3

50. Zhu ZW, Tang JJ, Chai XP. et al. Comparison of heart failure and 2019 novel coronavirus pneumonia in chest CT features and clinical characteristics. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E007. doi: 10.3760/cma.j.cn112148-20200218-00093. [Epub ahead of print]